{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:33:09Z","timestamp":1790706789684,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001275","name":"Oak foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Danish Psoriasis Association"},{"name":"Muskellaboratoriets Fond"},{"name":"Clara Hansens Mindelegat"},{"DOI":"10.13039\/501100010363","name":"Minister Erna Hamiltons Legat for Videnskab og Kunst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010363","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bispebjerg and Frederiksberg Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To explore the prognostic value of pre-specified comorbidities on treatment outcomes in PsA, and to compare baseline data with cutaneous psoriasis without arthritis and healthy controls (HC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients initiating conventional synthetic\/biological disease-modifying antirheumatic drugs were enrolled in this clinical observational cohort study, and data on comorbidities, and clinical and patient-reported outcomes were retrieved at baseline and after 4\u2009months. Pearson\u2019s chi-squared tests were performed to investigate the prognostic value of pre-specified comorbidities and achievement of ACR20, DAPSA50 and MDA. Mann\u2013Whitney U tests were used to compare OMERACT PsA Core Outcome Set (COS) measures at baseline and follow-up for the pre-specified comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 100 PsA patients were included at baseline. Statistically significantly fewer patients with obesity achieved DAPSA50 compared with patients without obesity (P\u00a0=0.035), and fewer patients with hypertension (P\u00a0=0.034) and Charlson Comorbidity Index (CCI) \u22651 (P\u00a0=0.027), respectively, achieved MDA compared with patients without these comorbidities. Patients with obesity, hypertension, widespread pain, and CCI \u22651 had significantly worse COS measures at follow-up compared with patients without these comorbidities. At baseline, patients with PsA had higher disease burden compared with patients with cutaneous psoriasis and HC, including higher pain (P\u00a0&amp;lt;0.001) and fatigue (P\u00a0&amp;lt;0.001) scores, and more widespread pain (P\u00a0=0.002).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Obesity, hypertension and CCI \u22651 were prognostic factors for poorer treatment outcome rates in PsA. Pain and fatigue were more frequently reported among patients with PsA compared with patients with cutaneous psoriasis and HC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>The Danish National Committee on Health Research Ethics: H-15009080; Data Protection Agency: 2012-58-0004; ClinicalTrials.gov: NCT02572700.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa780","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T20:13:12Z","timestamp":1604693592000},"page":"3289-3300","source":"Crossref","is-referenced-by-count":27,"title":["Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study"],"prefix":"10.1093","volume":"60","author":[{"given":"Christine","family":"Ballegaard","sequence":"first","affiliation":[{"name":"Department of Rheumatology, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Skougaard","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Guldberg-M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer V","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstine","family":"Amris","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja S","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"},{"name":"Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2021070122140688800_keaa780-B1","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"2021070122140688800_keaa780-B2","doi-asserted-by":"crossref","first-page":"e000588","DOI":"10.1136\/rmdopen-2017-000588","article-title":"Real-world burden of comorbidities in US patients with psoriatic arthritis","volume":"3","author":"Shah","year":"2017","journal-title":"RMD Open"},{"key":"2021070122140688800_keaa780-B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2020.02.001","article-title":"Epidemiology of depression and anxiety in patients with psoriatic arthritis: a systematic review and meta-analysis","author":"Zusman","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2021070122140688800_keaa780-B4","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar4049","article-title":"Hepatic steatosis, carotid plaques and achieving MDA in Psoriatic arthritis patients starting TNF-\u03b1 blockers treatment: a prospective study","volume":"14","author":"Di Minno","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2021070122140688800_keaa780-B5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"Di Minno","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2021070122140688800_keaa780-B6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12026-014-8595-z","article-title":"Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study","volume":"61","author":"Costa","year":"2015","journal-title":"Immunol Res"},{"key":"2021070122140688800_keaa780-B7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B8","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"H\u00f8jgaard","year":"2016","journal-title":"Rheumatology"},{"key":"2021070122140688800_keaa780-B9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3899\/jrheum.151491","article-title":"The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study","volume":"43","author":"Brikman","year":"2016","journal-title":"J Rheumatol"},{"key":"2021070122140688800_keaa780-B10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/acr.23693","article-title":"Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: a prospective cohort study","volume":"71","author":"H\u00f8jgaard","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2021070122140688800_keaa780-B11","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","article-title":"Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study","volume":"76","author":"Michelsen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3899\/jrheum.171034","article-title":"Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor","volume":"46","author":"Ogdie","year":"2019","journal-title":"J Rheumatol"},{"key":"2021070122140688800_keaa780-B13","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.121500","article-title":"Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis","volume":"40","author":"Husted","year":"2013","journal-title":"J Rheumatol"},{"key":"2021070122140688800_keaa780-B14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23333","article-title":"Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study","volume":"70","author":"Ballegaard","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2021070122140688800_keaa780-B15","doi-asserted-by":"crossref","first-page":"e13013","DOI":"10.1111\/eci.13013","article-title":"Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings","volume":"48","author":"Iannone","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"2021070122140688800_keaa780-B16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatol"},{"key":"2021070122140688800_keaa780-B17","first-page":"322","article-title":"Obesity, metabolic syndrome and other comorbidities in rheumatoid arthritis and psoriatic arthritis: influence on disease activity and quality of life","volume":"44","author":"Azevedo","year":"2019","journal-title":"Acta Reumatol Port"},{"key":"2021070122140688800_keaa780-B18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4081\/reumatismo.2020.1266","article-title":"Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with il-12\/23 and il-17 inhibitors. A multicenter prospective study","volume":"72","author":"Perrotta","year":"2020","journal-title":"Reumatismo"},{"key":"2021070122140688800_keaa780-B19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"2021070122140688800_keaa780-B21","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021070122140688800_keaa780-B22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/ard.2007.084244","article-title":"Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index","volume":"68","author":"Maksymowych","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American college of rheumatology 1990 criteria for the classification of fibromyalgia","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2021070122140688800_keaa780-B24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatology"},{"key":"2021070122140688800_keaa780-B25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/03009740151095402","article-title":"Adaptation into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life scale (RAQoL)","volume":"30","author":"Thorsen","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"2021070122140688800_keaa780-B26"},{"key":"2021070122140688800_keaa780-B27","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","article-title":"painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain","volume":"22","author":"Freynhagen","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2021070122140688800_keaa780-B28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0895-4356(98)00091-2","article-title":"The Danish SF-36 health survey: translation and preliminary validity studies","volume":"51","author":"Bjorner","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"2021070122140688800_keaa780-B29","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2021070122140688800_keaa780-B31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"Wolfe","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2021070122140688800_keaa780-B32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr.22107","article-title":"Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort","volume":"66","author":"Kristensen","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2021070122140688800_keaa780-B33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3899\/jrheum.110893","article-title":"Fibromyalgia identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia","volume":"39","year":"2012","journal-title":"J Rheumatol"},{"key":"2021070122140688800_keaa780-B34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2021070122140688800_keaa780-B35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/03009742.2012.715186","article-title":"Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-\u03b1 therapy","volume":"42","author":"Iannone","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"2021070122140688800_keaa780-B38","doi-asserted-by":"crossref","first-page":"e000934","DOI":"10.1136\/rmdopen-2019-000934","article-title":"Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial","volume":"5","author":"McInnes","year":"2019","journal-title":"RMD Open"},{"key":"2021070122140688800_keaa780-B39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","article-title":"Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management","volume":"52","author":"Russolillo","year":"2013","journal-title":"Rheumatology"},{"key":"2021070122140688800_keaa780-B40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41366-019-0505-y","article-title":"Obesity and pain: a systematic review","volume":"44","author":"Chin","year":"2020","journal-title":"Int J Obes"},{"key":"2021070122140688800_keaa780-B41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2021070122140688800_keaa780-B42","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B43","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register","volume":"49","author":"Saad","year":"2010","journal-title":"Rheumatology"},{"key":"2021070122140688800_keaa780-B44","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021070122140688800_keaa780-B45","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021070122140688800_keaa780-B47","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","article-title":"Societal costs and patients\u2019 experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study","volume":"76","author":"Kristensen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021070122140688800_keaa780-B48","year":"2017"},{"key":"2021070122140688800_keaa780-B49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3899\/jrheum.170449","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature","volume":"45","author":"Gossec","year":"2018","journal-title":"J Rheumatol"},{"key":"2021070122140688800_keaa780-B50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3899\/jrheum.160973","article-title":"Need for improvement in current treatment of psoriatic arthritis: study of an outpatient clinic population","volume":"44","author":"Michelsen","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/7\/3289\/38849961\/keaa780.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/7\/3289\/38849961\/keaa780.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:18:19Z","timestamp":1697048299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/7\/3289\/6039081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa780","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,12,16]]}}}